Antibodies targeting checkpoint molecules such as PD-1 have already shown therapeutic effects on non-small cell lung cancer and melanoma, and PD-L1 expression exhibited a positive correlation with response to PD-1 inhibition in those tumors [45, 46]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.